PACIFIC BIOSCIENCES CALIF IN's ticker is PACB and the CUSIP is 69404D108. A total of 215 filers reported holding PACIFIC BIOSCIENCES CALIF IN in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,355,500 | -35.2% | 1,838,982 | +3.3% | 0.00% | -42.9% |
| Q2 2023 | $23,679,666 | +17.5% | 1,780,426 | +2.3% | 0.01% | +16.7% |
| Q1 2023 | $20,153,936 | +55.9% | 1,740,409 | +10.1% | 0.01% | +50.0% |
| Q4 2022 | $12,927,623 | +43.5% | 1,580,394 | +1.8% | 0.00% | +33.3% |
| Q3 2022 | $9,010,000 | +22.2% | 1,552,107 | -6.9% | 0.00% | 0.0% |
| Q2 2022 | $7,372,000 | -50.2% | 1,667,879 | +2.5% | 0.00% | -25.0% |
| Q1 2022 | $14,815,000 | -54.5% | 1,627,942 | +2.3% | 0.00% | -60.0% |
| Q4 2021 | $32,559,000 | -11.9% | 1,591,325 | +10.1% | 0.01% | -16.7% |
| Q3 2021 | $36,942,000 | -26.3% | 1,445,845 | +0.8% | 0.01% | -29.4% |
| Q2 2021 | $50,158,000 | +10.5% | 1,434,300 | +5.3% | 0.02% | 0.0% |
| Q1 2021 | $45,374,000 | +44.0% | 1,362,149 | +12.2% | 0.02% | +41.7% |
| Q4 2020 | $31,504,000 | +182.0% | 1,214,472 | +7.3% | 0.01% | +140.0% |
| Q3 2020 | $11,170,000 | +241.4% | 1,131,613 | +19.3% | 0.01% | +150.0% |
| Q2 2020 | $3,272,000 | +21.1% | 948,189 | +7.4% | 0.00% | 0.0% |
| Q1 2020 | $2,701,000 | -39.3% | 882,629 | +2.0% | 0.00% | 0.0% |
| Q4 2019 | $4,447,000 | +1.6% | 865,098 | +2.1% | 0.00% | -33.3% |
| Q3 2019 | $4,375,000 | -11.0% | 847,697 | +4.4% | 0.00% | 0.0% |
| Q2 2019 | $4,915,000 | -13.4% | 812,359 | +3.5% | 0.00% | -25.0% |
| Q1 2019 | $5,675,000 | +1.9% | 784,912 | +4.3% | 0.00% | 0.0% |
| Q4 2018 | $5,568,000 | +52.7% | 752,343 | +11.6% | 0.00% | +100.0% |
| Q3 2018 | $3,646,000 | +67.2% | 673,850 | +9.7% | 0.00% | 0.0% |
| Q2 2018 | $2,181,000 | +105.0% | 614,288 | +18.4% | 0.00% | +100.0% |
| Q1 2018 | $1,064,000 | -5.7% | 518,737 | +21.4% | 0.00% | 0.0% |
| Q4 2017 | $1,128,000 | -47.4% | 427,202 | +4.5% | 0.00% | -50.0% |
| Q3 2017 | $2,146,000 | +118.1% | 408,638 | +47.9% | 0.00% | +100.0% |
| Q2 2017 | $984,000 | -46.2% | 276,259 | -21.9% | 0.00% | -50.0% |
| Q1 2017 | $1,830,000 | +45.8% | 353,817 | +7.1% | 0.00% | +100.0% |
| Q4 2016 | $1,255,000 | -53.1% | 330,223 | +10.7% | 0.00% | -66.7% |
| Q3 2016 | $2,674,000 | +180.9% | 298,364 | +120.5% | 0.00% | +200.0% |
| Q2 2016 | $952,000 | -3.4% | 135,300 | +16.6% | 0.00% | 0.0% |
| Q1 2016 | $986,000 | -23.8% | 116,000 | +17.8% | 0.00% | -50.0% |
| Q4 2015 | $1,294,000 | +312.1% | 98,500 | +15.1% | 0.00% | – |
| Q3 2015 | $314,000 | -36.4% | 85,600 | 0.0% | 0.00% | -100.0% |
| Q2 2015 | $494,000 | -1.2% | 85,600 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $500,000 | -25.6% | 85,600 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $672,000 | +59.6% | 85,600 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $421,000 | -20.6% | 85,600 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $530,000 | +15.7% | 85,600 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $458,000 | +2.2% | 85,600 | 0.0% | 0.00% | 0.0% |
| Q4 2013 | $448,000 | -10.6% | 85,600 | 0.0% | 0.00% | 0.0% |
| Q3 2013 | $501,000 | +127.7% | 85,600 | 0.0% | 0.00% | – |
| Q2 2013 | $220,000 | – | 85,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,660,000 | $24,206,000 | 11.49% |
| Data Collective II GP, LLC | 164,249 | $1,495,000 | 5.44% |
| Decheng Capital Management III (Cayman), LLC | 1,463,872 | $13,321,000 | 4.08% |
| SB Management Ltd | 1,886,107 | $17,164,000 | 3.33% |
| Casdin Capital, LLC | 7,990,652 | $72,715,000 | 3.26% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,225,395 | $11,151,000 | 2.20% |
| Jackson Square Partners, LLC | 22,542,589 | $205,137,000 | 2.04% |
| BOURNE LENT ASSET MANAGEMENT INC | 556,865 | $5,067,000 | 1.59% |
| ARK Investment Management | 27,259,521 | $248,062,000 | 1.04% |
| Nikko Asset Management Americas, Inc. | 14,021,205 | $127,873,000 | 0.94% |